Creating targeted T cells to treat acute myeloid leukemia
Official title: Development of chimeric antigen receptor T cells targeting cell surface U5 snRNP for the treatment of acute myeloid leukemia
Funded at Sloan-Kettering Inst Can Research · NIH-11121382 · Data updated 2026-11-12
This study is testing a new treatment for acute myeloid leukemia (AML) that uses specially designed immune cells to target a unique protein found only on AML cells, aiming to make the therapy safer and more effective for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 3, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $402,600 |
| NIH project number | 1R01CA291796-01A1 |
| Project ID | NIH-11121382 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have not responded well to existing treatments.
✕Less likely to help
Patients with other types of leukemia or those who have already received extensive treatment may not benefit from this research.
What this research studies
This research focuses on developing chimeric antigen receptor T cells that specifically target a unique protein found on the surface of acute myeloid leukemia (AML) cells. By identifying the U5 snRNP200 protein, which is present on AML cells but absent from normal blood cells, the researchers aim to create a more effective immunotherapy for patients with AML. The approach involves engineering T cells to recognize and attack these cancer cells, potentially leading to improved treatment outcomes. Patients may be involved in trials to assess the safety and effectiveness of this innovative therapy.
Why it matters
Potential benefit: If successful, this research could provide a new and effective immunotherapy option for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promise in using targeted T cell therapies for other cancers, indicating potential success for this novel approach in AML.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Daniyan, Anthony — Sloan-Kettering Inst Can Research
- Study coordinator: Daniyan, Anthony
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.